Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOT-HER3: Patritumab Deruxtecan in Early Breast Cancer
NCT04610528Phase 1Unknown
- Sponsor
- SOLTI
- Start
- Dec 2020
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of patritumab deruxtecan in breast cancer, sponsored by SOLTI. Primary endpoint: CelTIL score. Status: unknown.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04610528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610528.